We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+44.61%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$502M
AUM Growth
-$46.6M
Cap. Flow
-$131M
Cap. Flow %
-26.01%
Top 10 Hldgs %
39.38%
Holding
180
New
41
Increased
13
Reduced
50
Closed
76

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.2M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$10.6M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$7.73M
4
SAGE
Sage Therapeutics
SAGE
+$6.1M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$5.3M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$12.7M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$11.3M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.1M
4
UTHR icon
United Therapeutics
UTHR
+$9.43M
5
CLDX icon
Celldex Therapeutics
CLDX
+$6.76M

Sector Composition

Rank Sector Weight
1 Healthcare 39.26%
2 Consumer Staples 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCOR
76
DELISTED
Renovacor, Inc.
RCOR
$725K 0.14%
288,119
-5,164
-2% -$9.89K
CMMB
77
Chemomab Therapeutics
CMMB
$11.4M
$612K 0.12%
61,474
-5,552
-8% -$71.5K
ELDN icon
78
Eledon Pharmaceuticals
ELDN
$261M
$612K 0.12%
221,830
-140,707
-39% -$448K
ALNY icon
79
Alnylam Pharmaceuticals
ALNY
$27.5B
$560K 0.11%
2,800
-58,437
-95% -$11.1M
TARA icon
80
Protara Therapeutics
TARA
$220M
$558K 0.11%
188,664
-69,189
-27% -$234K
AUTL
81
Autolus Therapeutics
AUTL
$397M
$556K 0.11%
260,087
-62,130
-19% -$184K
BLCM
82
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$537K 0.11%
448,101
-75,247
-14% -$95.9K
OKUR
83
OnKure Therapeutics
OKUR
$154M
$521K 0.1%
15,582
-2,978
-16% -$97.8K
CLNN icon
84
PUT
Clene
CLNN
$64M
$496K 0.1%
+8,870
New +$588K
IMTX icon
85
Immatics
IMTX
$1.18B
$490K 0.1%
49,031
-108,159
-69% -$1.17M
RETA
86
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$463K 0.09%
+18,400
New +$510K
ANEB
87
DELISTED
Anebulo Pharmaceuticals
ANEB
$437K 0.09%
156,203
-24,996
-14% -$88.8K
CLVS
88
DELISTED
Clovis Oncology, Inc.
CLVS
$430K 0.09%
361,518
-60,821
-14% -$94.8K
FNCH
89
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$397K 0.08%
7,918
-3,099
-28% -$216K
SYBX
90
DELISTED
Synlogic
SYBX
$292K 0.06%
20,450
-11,174
-35% -$171K
CNTB
91
Connect Biopharma Holdings
CNTB
$127M
$283K 0.06%
219,501
-458,358
-68% -$551K
GOSS icon
92
PUT
Gossamer Bio
GOSS
$82.9M
$209K 0.04%
+17,400
New +$216K
VRNA
93
DELISTED
Verona Pharma
VRNA
$193K 0.04%
315,131
+15,131
+5% +$128K
ARKK icon
94
ARK Innovation ETF
ARKK
$5.66B
$171K 0.03%
+4,519
New +$201K
PRAX icon
95
CALL
Praxis Precision Medicines
PRAX
$8.58B
$168K 0.03%
4,947
-2,200
-31% -$110K
ASLN
96
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$146K 0.03%
20,511
-3,758
-15% -$96.9K
MITO
97
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
$134K 0.03%
435,516
-66,320
-13% -$18.9K
CABA icon
98
Cabaletta Bio
CABA
$437M
$109K 0.02%
168,623
-775,808
-82% -$934K
RETA
99
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$102K 0.02%
4,064
-16,741
-80% -$464K
SPPI
100
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$76K 0.02%
+176,980
New +$174K
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Ikarian Capital held 180 positions worth $502M, down 8.5% from $548M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital withdrew a net $131M in Q3 2022, closing 76 positions and reducing 50 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $12.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 43% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Ikarian Capital opened a new position in Prometheus Biosciences, Inc. Common Stock worth $13.6M.

  • Ikarian Capital's largest Q3 2022 buy was Prometheus Biosciences, Inc. Common Stock: 231,181 shares worth $13.6M.
  • Ikarian Capital added most to IVERIC bio, Inc. Common Stock in Q3 2022, an estimated $12.2M increase.
  • Ikarian Capital's biggest Q3 2022 reduction was Alnylam Pharmaceuticals, cutting an estimated $11.1M.
  • Ikarian Capital fully exited Karuna Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $12.7M.
  • Ikarian Capital's ten largest holdings make up 39% of its $502M portfolio in Q3 2022.
  • Ikarian Capital opened 41 new positions and closed 76 in Q3 2022.
  • Ikarian Capital's portfolio value fell 8.5% quarter-over-quarter to $502M.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.